Recently, Dahua Pharmaceutical Company held the second meeting of its fifth board of directors. The chairman of the company, Yu Jianzhong, presided over the meeting, all members of the board of directors attended the meeting, members of the supervisory board, and members of the company's leadership attended the meeting as observers.

The meeting listened to the company's business situation in 2015, work plan for 2016, financial work report for 2015, profit distribution plan, and discussed the feasibility report of the new project "Nucleic Acid Diagnostic Reagent". The attending directors carefully reviewed and evaluated the report, and expressed their opinions and suggestions. After a written vote, the above proposal was unanimously passed.

The meeting believed that in the face of the complex and severe domestic and international situation at that time, Dahua Pharmaceutical Company overcame difficulties and rose against the trend. In 2015, it successively passed the GMP audit of the World Health Organization and the official audit of the Brazilian Medicines Agency. While consolidating product quality, it also developed the market in South America and expanded the width of the skin embedding market. The board of directors gave full recognition to this.

Chairman Yu Jianzhong emphasized that Dahua Pharmaceutical Company needs to enhance confidence, firm beliefs, be not afraid of difficulties, and fully organize its production and operation work in the second half of the year. Firstly, for the development of the new project "nucleic acid diagnostic reagents", it is necessary to plan reasonably and strive to achieve good development of the new project; The second is to prepare for the production of 2 million sets of leather burial products, in order to cope with the large-scale order procurement in the second half of the year and next year, achieve cost reduction and efficiency improvement, and form sustainable international competitiveness; The third is to strengthen the self construction of the board of directors, conscientiously implement the requirements of the company law and articles of association, and ensure the compliance and professionalization of the operation of the board of directors.